Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director | February 18, 2026 | February 20, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | PRINCIPAL FINANCIAL OFFICER | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 247,047 |
Reported balance
After 2026-02-18 transaction · row 1
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 48,828 · Balance 247,047 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.
SANGAMO THERAPEUTICS, INC
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 660,042 |
Reported balance
After 2026-01-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-22 · Tax withholding · Disposed 36,676 · Balance 660,042 F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2: Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
F2: Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:26 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000051 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,047 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 36,676 | $0.40 | $14,615.39 |
DisclosureSEC source: 0001779092-26-000002 · form4-01262026_090129.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · PRINCIPAL FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660,042 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 52,387 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 5,010 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 2,544 | $0.42 | $1,059.83 |
DisclosureSEC source: 0001779092-25-000007 · form4-11262025_091116.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · PRINCIPAL FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,718 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2025 of $0.4166/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,466 shares resulting from the November 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 5,010 shares will vest on February 24, 2026, (b) 89,063 shares subject to Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 21:00 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 45,225 | $0.66 | $29,848.50 |
DisclosureSEC source: 0001779092-25-000005 · form4-10242025_051005.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · PRINCIPAL FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 699,262 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on October 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on October 22, 2025 of $0.66/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 43,837 shares resulting from the October 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 89,063 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 10,020 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 24, 2025 Filed Aug 27, 2025 00:00 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,792 | $0.59 | $1,050.65 |
DisclosureSEC source: 0001415889-25-023074 · form4-08272025_120810.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744,487 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 22, 2025 of $0.5863/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,218 shares resulting from the August 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 10,020 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 178,125 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| July 22, 2025 Filed Jul 24, 2025 20:59 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 31,866 | $0.48 | $15,289.31 |
DisclosureSEC source: 0001415889-25-020246 · form4-07242025_080720.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 746,279 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on July 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on July 22, 2025 of $0.4798/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 57,197 shares resulting from the July 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 178,125 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 15,030 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 24, 2025 Filed May 28, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,792 | $0.47 | $848.15 |
DisclosureSEC source: 0001415889-25-014693 · form4-05282025_040504.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778,145 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,217 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 15,030 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 267,188 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 20:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 31,866 | $0.78 | $24,737.58 |
DisclosureSEC source: 0001415889-25-011285 · form4-04242025_080437.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,937 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on April 22, 2025 of $0.7763/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 57,196 shares resulting from the April 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 267,188 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-005705 · form4-02262025_100216.xml · derivative · entry 4 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2035-02-24 F7 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005705 · form4-02262025_100216.xml · nonDerivative · entry 3 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 811,803 F5 · shares: Represents shares of common stock issuable upon settlement of a RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F6 · balance_after: Includes: (a) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026, (b) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 120,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 22:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,375 | $0.96 | $1,314.64 |
DisclosureSEC source: 0001415889-25-005705 · form4-02262025_100216.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 691,803 F3 · shares: Represents shares underlying the portion of an RSU grant that vested on February 25, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 25, 2025 of $0.9561/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F4 · balance_after: Includes:(a) 2,469 shares resulting from the February 25, 2025 final vesting installment of the Reporting Person's February 25, 2022 RSU grant, (b) 20,039 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,792 | $1.00 | $1,792.00 |
DisclosureSEC source: 0001415889-25-005705 · form4-02262025_100216.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 693,178 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2025 of $1.00/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,218 shares resulting from the February 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 20,039 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final quarterly installment on February 25, 2025, and (c) 356,250 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:38 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003207 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,219 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 129,242 | $1.15 | $148,628.30 |
DisclosureSEC source: 0001415889-25-002019 · form4-01242025_040104.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 694,970 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2025 of $1.15/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 227,008 shares resulting from the January 22, 2025 vesting installment of the Reporting Person's January 22, 2024 RSU grant, and the remaining 356,250 shares will vest in successive equal quarterly installments through January 22, 2026, (b) 3,844 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in one final installment on February 25, 2025 and (c) 25,049 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,371 | $1.94 | $2,659.74 |
DisclosureSEC source: 0001415889-24-027703 · form4-11262024_091108.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 824,212 F4 · shares: Represents shares underlying the portion of an RSU grant that vested on November 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 25, 2024 of $1.94/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes:(a) 2,473 shares resulting from the November 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 3,844 shares will vest in one final installment on February 25, 2025, (b) 25,049 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| November 24, 2024 Filed Nov 26, 2024 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,787 | $1.88 | $3,359.56 |
DisclosureSEC source: 0001415889-24-027703 · form4-11262024_091108.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 825,583 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 22, 2024 of $1.88/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,223 shares resulting from the November 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 25,049 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 7,688 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2024 Filed Aug 27, 2024 20:37 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,371 | $0.86 | $1,179.06 |
DisclosureSEC source: 0001415889-24-022308 · form4-08272024_080835.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,370 F4 · shares: Represents shares underlying the portion of an RSU grant that vested on August 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes:(a) 2,473 shares resulting from the August 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 7,688 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 30,059 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| August 24, 2024 Filed Aug 27, 2024 20:37 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,787 | $0.86 | $1,536.82 |
DisclosureSEC source: 0001415889-24-022308 · form4-08272024_080835.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,741 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 23, 2024 of $0.86/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,223 shares resulting from the August 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 30,059 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 11,532 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:42 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 892 | $0.61 | $542.07 |
DisclosureSEC source: 0001415889-24-016686 · form4-06132024_080609.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,528 F1 · shares: Represents shares underlying the portions of RSU grants that vested on June 11, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 11, 2024 of $0.6077/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,608 shares resulting from the June 11, 2024 final vesting installment of the Reporting Person's June 11, 2021 RSU grant, (b) 11,532 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 35,069 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 25, 2024 Filed May 29, 2024 20:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,371 | $0.60 | $822.60 |
DisclosureSEC source: 0001415889-24-014779 · form4-05292024_080536.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,420 F4 · shares: Represents shares underlying the portions of RSU grants that vested on May 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes:(a) 2,472 shares resulting from the May 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 11,532 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024, (c) 35,069 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:57 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,787 | $0.60 | $1,072.20 |
DisclosureSEC source: 0001415889-24-014779 · form4-05292024_080536.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,791 F1 · shares: Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 3,222 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 35,069 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 15,375 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2024 Filed Feb 27, 2024 22:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,453 | $1.13 | $3,901.89 |
DisclosureSEC source: 0001415889-24-005548 · form4-02272024_100240.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 834,578 F4 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the 2018 EIP). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F5 · balance_after: Includes: (a) 2,706 shares resulting from the February 25, 2024 final vesting installment of the Reporting Person's February 25, 2021 RSU grant, (b) 2,269 shares resulting from the February 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 15,375 shares will vest in successive equal quarterly installments through February 25, 2025, (c) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024, (d) 40,078 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (e) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. Read SEC document |
| February 24, 2024 Filed Feb 27, 2024 22:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,474 | $1.13 | $6,185.62 |
DisclosureSEC source: 0001415889-24-005548 · form4-02272024_100240.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838,031 F1 · shares: Represents shares underlying the portions of RSU grants that vested on February 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 23, 2024 of $1.13/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 7,886 shares resulting from the February 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 40,078 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 19,219 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004304 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,644 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 712,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001756 · form4-01242024_090116.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843,505 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP). F2 · balance_after: Includes: (a) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 19,219 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (d) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| November 25, 2023 Filed Nov 28, 2023 21:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,329 | $0.38 | $507.81 |
DisclosureSEC source: 0001209191-23-056778 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,005 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,515 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 19,219 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (d) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 20:14 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,329 | $0.77 | $1,023.33 |
DisclosureSEC source: 0001209191-23-047585 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,334 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,515 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 23,063 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter and (d) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 20:55 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 864 | $1.19 | $1,028.16 |
DisclosureSEC source: 0001209191-23-036788 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,663 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 11, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 9, 2023 of $1.19/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,636 shares resulting from the June 11, 2023 vesting installment of the Reporting Person's June 11, 2021 RSU grant and 2,500 shares subject to such RSU grant that will vest in one final installment on June 11, 2024, (b) 26,907 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 53,438 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 2,475 shares acquired on May 31, 2023 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 1,328 | $1.33 | $1,766.24 |
DisclosureSEC source: 0001209191-23-032906 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,052 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of $1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 2,515 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 26,907 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 5,000 shares subject to the Reporting Person's June 11, 2022 RSU grant that will vest in two remaining installments of 2,500 shares on each of June 11, 2023 and 2024, (c) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 53,438 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. F3 · balance_after: The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| March 25, 2023 Filed Mar 28, 2023 21:04 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 345 | $1.66 | $572.70 |
DisclosureSEC source: 0001209191-23-021427 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,380 F1 · shares: Represents shares of common stock underlying the portion of a restricted stock unit ("RSU") grant that vested on March 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on March 24, 2023 of $1.66/share, pursuant to the terms of the Issuer's Amended and Restated Equity Incentive Plan (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 655 shares resulting from the March 25, 2023 final vesting installment of the Reporting Person's March 25, 2020 RSU grant, (b) 4,584 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (c) 30,750 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in 8 successive equal quarterly installments after February 25, 2023, and (e) 5,000 shares subject to the Reporting Person's June 11, 2022 RSU grant that will vest in two remaining installments of 2,500 shares on each of June 11, 2023 and 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2023 Filed Mar 6, 2023 22:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 7,030 | $2.66 | $18,699.80 |
DisclosureSEC source: 0001209191-23-016390 · doc4.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,725 F3 · shares: Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes 722 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. F4 · balance_after: Includes: (a) 3,599 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 2,999 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 4,584 shares subject to such RSU grant that will vest in one final installment on February 25, 2024, (c) 6,706 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 30,750 shares will vest in 8 successive equal quarterly installments thereafter, (continued in footnote 5) F5 · balance_after: (d) 1,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in one final installment on March 25, 2023 and (e) 5,000 shares subject to the Reporting Person's June 11, 2022 RSU grant that will vest in two remaining installments of 2,500 shares on each of June 11, 2023 and 2024. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 249,375 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-23-016390 · doc4.xml · derivative · entry 3 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,375 Underlying: Common Stock · 249,375 shares Expires 2033-02-23 F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 24, 2023 Filed Mar 6, 2023 22:07 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 53,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016390 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,755 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 722 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:47 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004886 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,624 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| June 11, 2022 Filed Jun 14, 2022 20:37 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 842 | $3.76 | $3,165.92 |
DisclosureSEC source: 0001209191-22-036702 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,617 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 11, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on June 10, 2022 of $3.76/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 1,658 shares resulting from the June 11, 2022 annual vesting installment of the Reporting Person's June 11, 2021 RSU grant and 5,000 shares subject to such grant that will vest in two remaining annual installments of 2,500 shares on each of June 11, 2023 and 2024, (b) 5,501 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (continued in footnote 3) F3 · balance_after: (d) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, and (e) 1,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in one final annual installment on March 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 687 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 11, 2022 Filed Feb 6, 2023 23:28 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 864 | $3.76 | $3,248.64 |
DisclosureSEC source: 0001209191-23-007355 · doc4a.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,595 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on June 11, 2022 which were surrendered by the Reporting Person to the Issuer solely for mandatory tax withholding purposes using the Issuer's closing stock price on June 10, 2022 of $3.76/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. F2 · balance_after: Includes: (a) 1,658 shares resulting from the June 11, 2022 annual vesting installment of the Reporting Person's June 11, 2021 RSU grant and 5,000 shares subject to such grant that will vest in two remaining annual installments of 2,500 shares on each of June 11, 2023 and 2024, (b) 5,501 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (c) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (continued in footnote 3) F3 · balance_after: (d) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, and (e) 1,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in one final annual installment on March 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 687 shares acquired on May 31, 2022 under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 21:08 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 662 | $4.83 | $3,197.46 |
DisclosureSEC source: 0001209191-22-025809 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,772 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on April 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on April 25, 2022 of $4.83/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 1,255 shares resulting from the April 25, 2022 final annual vesting installment of the Reporting Person's April 25, 2019 RSU grant, (b) 7,500 shares subject to the Reporting Person's June 11, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of June 11, 2022, 2023 and 2024, (c) 5,501 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (d) 9,167 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (continued in footnote 3) F3 · balance_after: (e) 41,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, and (f) 1,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in one final annual installment on March 25, 2023. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:41 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 345 | $5.75 | $1,983.75 |
DisclosureSEC source: 0001209191-22-021495 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,434 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on March 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on March 25, 2022 of $5.75/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 655 shares resulting from the March 25, 2022 vesting of Reporting Person's March 25, 2020 RSU grant and 1,000 shares subject to such RSU grant that will vest in one final annual installment on March 25, 2023, (b) 1,917 shares subject to Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022, (c) 7,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of June 11, 2022, 2023 and 2024, (d) 5,501 shares subject to Reporting Person's February 25, 2020 RSU grant that will vest in one final annual installment on February 25, 2023, (continued in footnote 3) F3 · balance_after: (e) 9,167 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, and (f) 41,000 shares subject to Reporting Person's February 25, 2022 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 110,700 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014170 · doc4.xml · derivative · entry 3 Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,700 Underlying: Common Stock · 110,700 shares Expires 2032-02-24 F6 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014170 · doc4.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,779 F5 · shares: Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:18 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 3,474 | $5.90 | $20,496.60 |
DisclosureSEC source: 0001209191-22-014170 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,779 F1 · shares: Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes: (a) 3,609 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 5,501 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (b) 2,999 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 9,167 shares subject to such RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (c) 2,000 shares subject to Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares on each of March 25, 2022 and 2023, (d) 1,917 shares subject to Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022 and (see footnote 3) F3 · balance_after: (e) 7,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of June 11, 2022, 2023 and 2024. The vesting of all such grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F4 · balance_after: Includes 426 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:03 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 20,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004810 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,887 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2023. Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 00:15 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 11,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-011496 · form4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,340 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over three years beginning November 19, 2021. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 23:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.76 | $0.00 |
DisclosureSEC source: 0001209191-21-040405 · doc4.xml · derivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · SVP, CFO, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-10 F5 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the June 11, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 23:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040405 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · SVP, CFO, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,827 F1 · shares: Represents 7,500 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 11, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 2,000 shares acquired by the Reporting Person on April 30, 2021 under the Issuer's 2010 Employee Stock Purchase Plan, as amended; and (b) 199 shares acquired by the Reporting Person on May 28, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. F3 · balance_after: This amount also includes (a) 1,917 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest on April 25, 2022; (b) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; (c) 13,750 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date; and (continued in footnote 4) F4 · balance_after: (d) 2,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares each shares on March 25, 2022 and 2023, respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| April 25, 2021 Filed Apr 28, 2021 00:49 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 662 | $11.71 | $7,752.02 |
DisclosureSEC source: 0001209191-21-028744 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,128 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on April 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on April 23, 2021 of $11.71/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 1,254 shares resulting from the April 25, 2021 vesting of the Reporting Person's April 25, 2019 RSU grant and 1,917 shares subject to such RSU grant that will vest on April 25, 2022; (b) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; (c) 13,750 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date; and (continued in footnote 3) F3 · balance_after: (d) 2,000 shares subject to the Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares each shares on March 25, 2022 and 2023, respectively. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 23:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 345 | $12.27 | $4,233.15 |
DisclosureSEC source: 0001209191-21-023480 · doc4.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,790 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on March 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on March 25, 2021 of $12.27/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 655 shares resulting from the March 25, 2021 vesting of the Reporting Person's March 25, 2020 RSU grant and 2,000 shares subject to such RSU grant that will vest in two remaining annual installments of 1,000 shares and 1,000 shares on March 25, 2022 and 2023 respectively; (b) 3,833 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; (c) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; and F3 · balance_after: (d) 44,000 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| March 25, 2021 Filed Apr 28, 2021 00:46 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 345 | $12.27 | $4,233.15 |
DisclosureSEC source: 0001209191-21-028742 · doc4a.xml · nonDerivative · entry 1 Duraibabu Prathyusha · CIK 0001779092 · VP, PFO and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,790 F1 · shares: Represents shares underlying the portion of restricted stock unit ("RSU") grant that vested on March 25, 2021 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on March 25, 2021 of $12.27/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended"). F2 · balance_after: Includes: (a) 655 shares resulting from the March 25, 2021 vesting of the Reporting Person's March 25, 2020 RSU grant and 2,000 shares subject to such RSU grant that will vest in two remaining annual installments of 1,000 shares and 1,000 shares on March 25, 2022 and 2023 respectively; (b) 3,833 shares subject to the Reporting Person's April 25, 2019 RSU grant that will vest in two remaining annual installments of 1,916 shares and 1,917 shares on April 25, 2021 and 2022 respectively; (c) 11,000 shares subject to the Reporting Person's February 25, 2020 RSU grant that will vest in two remaining annual installments of 5,499 shares and 5,501 shares on February 25, 2022 and 2023 respectively; and (continued in Footnote 3) F3 · balance_after: (d) 13,750 shares subject to the Reporting Person's February 25, 2021 grant that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date. The vesting of all such RSUs is subject to the Reporting Person's continued service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. F4 · balance_after: This Form 4/A is being filed solely to correct the stated amount included in Footnote 3 on the Form 4 filed on behalf of the Reporting Person on March 29, 2021 to be 13,750 shares subject to RSUs vesting which was erroneously reported to be 44,000 shares in such Footnote 3. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015525 · doc4.xml · derivative · entry 3 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2031-02-24 F5 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 25, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:12 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015525 · doc4.xml · nonDerivative · entry 2 Duraibabu Prathyusha · CIK 0001779092 · VP Principal Acct. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,135 F4 · shares: Represents 44,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on February 25, 2021 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.